BusinessThetis Builds Scientific Advisory Board to Guide Development of Immuno-Resolving Therapies for IBDBy Nasdaq OMXDec 11, 2017, 3:35 PM UTC
BusinessThetis Pharmaceuticals Awarded $2.3 Million Fast-Track NIH Grant to Develop Immuno-Resolving Therapy for Inflammatory Bowel DiseaseBy Nasdaq OMXNov 16, 2017, 5:35 PM UTC
